Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.48 USD | -0.31% | -6.43% | -26.86% |
May. 20 | HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target | MT |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
Business Summary
Number of employees: 234
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 20-06-30 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | Jan. 16 |
Chief Operating Officer | 52 | 22-08-31 | |
Jeremy Duffield
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-12-31 |
Ann Lee
CTO | Chief Tech/Sci/R&D Officer | 62 | 21-09-30 |
Mohammed Asmal
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fubao Wang
LAW | General Counsel | - | - |
Karen Brown
LAW | General Counsel | - | - |
Niamh Alix
HRO | Human Resources Officer | - | 22-05-31 |
Carman Alenson
AUD | Comptroller/Controller/Auditor | 58 | 21-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 21-11-30 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 20-08-31 |
Michael Kelly
BRD | Director/Board Member | 67 | 21-10-31 |
David Schenkein
BRD | Director/Board Member | 66 | 19-09-12 |
Chief Executive Officer | 70 | 20-06-30 | |
Director/Board Member | 46 | 23-05-09 | |
Thomas Cahill
BRD | Director/Board Member | 37 | 21-10-31 |
Wendy Chung
BRD | Director/Board Member | 55 | 21-10-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 120,030,813 | 88,249,113 ( 73.52 %) | 0 | 73.52 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.86% | 749M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- PRME Stock
- Company Prime Medicine, Inc.